Opko Health Inc OPK

NAS: OPK | ISIN: US68375N1037 24/03/2023

1,300 USD (+3,17%)

(+3,17%) 24/03/2023

Grafiek Opko Health Inc

Grafiek Opko Health Inc

1 dag1d 3,17%
1 week1w -3,70%
1 maand1m 15,04%
3 maanden3m 21,50%
6 maanden6m -28,18%
1 jaar1j -62,96%
5 jaar5j -60,84%

Opko Health Inc in het nieuws

Toon enkel gratis nieuws

9 februari 2023 · BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings · Persbericht

16 maart 2022 · GeneDx Announces Discovery of 200 New and Expanded Genetic Conditions · Persbericht

1 maart 2022 · Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease · Persbericht

29 november 2021 · BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S. · Persbericht

21 september 2021 · GeneDx Announces the Sequencing of More Than 300,000 Clinical Patient Exomes · Persbericht

16 augustus 2021 · BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business · Persbericht

22 juni 2021 · BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry · Persbericht

27 april 2021 · Major League Soccer Renews with BioReference Laboratories as COVID-19 Testing Provider for Second Year · Persbericht

1 april 2021 · BioReference Laboratories Expands Its Major League Sports Relationships with Addition of Major League Baseball · Persbericht

26 maart 2021 · BioReference Laboratories Expands COVID-19 School Testing Program · Persbericht

336x280

Profiel Opko Health Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.opko.com

Hoofdzetel: Miami, Florida Verenigde Staten

CEO: Phillip Frost

Werknemers: 5.269

Aandelen Opko Health Inc

Beurswaarde: 973,54 miljoen USD

Effecten: 772,65 miljoen

Winst per aandeel (12 maand): PLUS

Beta: 1,55

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe